I have spent most of my MS-life working with Biozzi mice. These were made by Guido Biozzi in Paris to study the genetics of the immune response. At each generation he paired mice making high levels of antibody together and those making low levels of antibody (ABL) after immunization. After about 10-20 generations he made distinct lines. There was the ABH line that made high levels of antibodies that got EAE after immunization and then there are ABL with make low antibody responses and dont get EAE.
I have been bled and swabbed every month since last summer to measure my COVID response and foolishly they have given me £25 every time to do this (Yes what a waste of money!). Now apparently I have been selected to be part of an ABH and ABL study to measure responses to COVID-19 vaccines following assessment of my DNA.
It took 6 goes to get a hepatitits B response (normally you have 3) and have not made a great COVID-19 vaccine response so I am guessing I am in the ABL group, destined for symptomatic COVID-19 (because I dont produce a great vaccine response), when I get infected in the future. So when I am telling you (CD20-depleting antibody and fingolimod) stuff I am telling myself it too?
When I have been vaccinated I have had no adverse effect responses due to the injection, maybe because I have made a crap response, but many people are not like me and get reactions this is called reactogenicity. Now I would say this is not a measure of your antibody response but it could be and if you have demyelinated lesions these can be made more problematic. However, I suspect you are better qualified than I on this I but here are the experiences of other people. But please consider to get your boosters as the adverse effects are laregly temporary
Background and objectives: There are limited data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine reactogenicity in persons with multiple sclerosis (PwMS) and how reactogenicity is affected by disease-modifying therapies (DMTs). The objective of this retrospective cross-sectional study was to generate real-world multiple sclerosis-specific vaccine safety information, particularly in the context of specific DMTs, and provide information to mitigate specific concerns in vaccine hesitant PwMS.
Methods: Between 3/2021 and 6/2021, participants in iConquerMS, an online people-powered research network, reported SARS-CoV-2 vaccines, experiences of local (itch, pain, redness, swelling, or warmth at injection site) and systemic (fever, chills, fatigue, headache, joint pain, malaise, muscle ache, nausea, allergic, and other) reactions within 24 hours (none, mild, moderate, and severe), DMT use, and other attributes.
Results: In 719 PwMS, 64% reported experiencing a reaction after their first vaccination shot, and 17% reported a severe reaction. The most common reactions were pain at injection site (54%), fatigue (34%), headache (28%), and malaise (21%). Younger age, being female, prior SARS-CoV-2 infection, and receiving the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vs BNT162b2 (Pfizer-BioNTech) vaccine were associated with experiencing a reaction after the first vaccine dose. Similar relationships were observed for a severe reaction, including higher odds of reactions among PwMS with more physical impairment and lower odds of reactions for PwMS on an alpha4-integrin blocker or sphingosine-1-phosphate receptor modulator. In 442 PwMS who received their second vaccination shot, 74% reported experiencing a reaction, whereas 22% reported a severe reaction. Reaction profiles after the second shot were similar to those reported after the first shot. Younger PwMS and those who received the mRNA-1273 (Moderna) vs BNT162b2 vaccine reported higher reactogenicity after the second shot, whereas those on a sphingosine-1-phosphate receptor modulator or fumarate were significantly less likely to report a reaction.
Discussion: SARS-CoV-2 vaccine reactogenicity profiles and the associated factors in this convenience sample of PwMS appear similar to those reported in the general population. PwMS on specific DMTs were less likely to report vaccine reactions. Overall, the short-term vaccine reactions experienced in the study population were mostly self-limiting, including pain at the injection site, fatigue, headache, and fever.
General Disclaimer: Please note that the opinions expressed here are those of the author and do not necessarily reflect the positions of the Barts and The London School of Medicine and Dentistry, nor Barts Health NHS Trust and are not meant to be interpreted as personal clinical advice. Please note that Professor Gavin Giovannoni has no responsibility for this blog.